2024

• Gjorup, C., Woodford, R., Li, I., Carlino, M., Ch'ng, S., Chung, D., Hsiao, E., Lo, S., London, K., Long, G., Menzies, A., Nieweg, O., Pennington, T., Rtshiladze, M., Saw, R., Scolyer, R., Shannon, K., Spillane, A., Stretch, J., Thompson, J., Varey, A., van Akkooi, A. (2024). ASO Visual Abstract: Role of Concurrent Ultrasound Surveillance of Sentinel Node‑Positive Node Fields in Melanoma Patients Having Routine Cross‑Sectional Imaging. Annals of Surgical Oncology, 31(3), 1882-1883. [More Information]
• Anderson, A., Lo, S., Guitera, P. (2024). Commentary: Real-world post-deployment performance of a novel machine learning-based digital health technology for skin lesion assessment and suggestions for post-market surveillance. Frontiers in Medicine, 11, 1345659. [More Information]
• Pereira, A., Pampena, R., Longo, C., Guitera, P., Hirata, S., Pietkiewicz, P., Menzies, S., Brancaccio, G., Collgros Totosaus, H., Argenziano, G., Lo, S., et al (2024). Dermoscopy of Lentiginous Melanomas and Equivocal Benign Pigmented Macules of the Scalp: A Case-Control Multicentric Study. Dermatology, 240(1), 132-141. [More Information]
• Stassen, R., Maas, C., Van Der Veldt, A., Lo, S., Saw, R., Varey, A., Scolyer, R., Long, G., Thompson, J., Rutkowski, P., van Akkooi, A., et al (2024). Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis. The Lancet Oncology, 25(4), 509-517. [More Information]
• Menzies, A., Emmett, L., Kapoor, R., Rawson, R., Stretch, J., Thompson, J., Spillane, A., Rizos, H., Scolyer, R., Long, G., Lo, S., Saw, R., Gonzalez, M., Ch'ng, S., Nieweg, O., Shannon, K., Ferguson, P., et al (2024). Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma. Annals of Oncology. [More Information]
• Ehizogie, E., Maghari, I., Lo, S., Albrecht, J. (2024). Hidradenitis suppurativa, systemic inflammatory response syndrome and sepsis: a database study. British Journal of Dermatology, 191(3), 451-453. [More Information]
• Martin, A., Cust, A., Lo, S., Morton, R., Kasparian, N., Collgros Totosaus, H., Teh, N., Martin, L., Guitera, P. (2024). Mobile teledermoscopy for patients at high risk of cutaneous melanoma: A single-arm, feasibility study of a clinical intervention at two tertiary centres (MOBILEMEL). Journal of the European Academy of Dermatology and Venereology. [More Information]
• Williams, G., Quinn, T., Lo, S., Guitera, P., Scolyer, R., Thompson, J., Ch'ng, S. (2024). Mohs micrographic surgery for the treatment of invasive melanoma: A systematic review with meta-analyses. Journal of the European Academy of Dermatology and Venereology. [More Information]
• Lo, S., Varey, A., El Sharouni, M., Scolyer, R., Thompson, J. (2024). Online tools for predicting melanoma survival: Including sentinel node status as a variable improves prediction accuracy. Journal of the European Academy of Dermatology and Venereology, 38(2), e182-e184. [More Information]
• Smith, J., Espinoza, D., Smit, A., Gallo, B., Smith, A., Lo, S., Guitera, P., Martin, L., Cust, A. (2024). Patient demographic characteristics and risk factors associated with sun protection behaviours in specialist melanoma clinics. Australasian Journal of Dermatology. [More Information]
• Bagge, R., Thompson, J., Varey, A., Wong, S., Lyth, J., Bartlett, E., Mikiver, R., Marchetti, M., Lo, S., van Akkooi, A., Scolyer, R., et al (2024). Population-Based Validation of the MIA and MSKCC Tools for Predicting Sentinel Lymph Node Status. JAMA Surgery, 159(3), 260-268. [More Information]
• Varey, A., Li, I., El Sharouni, M., Simon, J., Dedeilia, A., Ch'ng, S., Saw, R., Spillane, A., Shannon, K., Pennington, T., Rtshiladze, M., Stretch, J., Nieweg, O., van Akkooi, A., Scolyer, R., Long, G., Thompson, J., Lo, S., et al (2024). Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator. Journal of Clinical Oncology, 42(10), 1169-1180. [More Information]
• Ni, Y., Watts, C., Scolyer, R., Madronio, C., Armstrong, B., Morton, R., Menzies, S., Mann, G., Thompson, J., Cust, A., Lo, S. (2024). Prognosis for people with multiple primary melanomas compared with a single primary melanoma. Journal Of The American Academy Of Dermatology, 90(1), 170-174. [More Information]
• Ho, G., Collgros Totosaus, H., Sinz, C., Melhoranse-Gouveia, B., Gallo, B., Chew, C., Ip, K., Koutsis, J., Lo, S., Schwartz-Aldea, R., Ferguson, P., Martin, L., Smith, A., Cust, A., Guitera, P., et al (2024). Remote cutaneous confocal microscopy: A multicentric prospective study evaluating diagnostic accuracy for melanoma and keratinocyte carcinoma in tertiary settings. Journal Of The American Academy Of Dermatology. [More Information]
• Rogiers, A., Menzies, A., Long, G., Dimitriou, F., Lobon, I., Harvey, C., Vergara Correa, I., Esteves Domingues Pires da Silva, I., Lo, S., Scolyer, R., Carlino, M. (2024). Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy. European Journal of Cancer, 198, 113506. [More Information]
• Hepner, A., Neyns, B., Haydon, A., Michielin, O., Mangana, J., Klein, O., Shoushtari, A., Warner, A., Ascierto, P., McQuade, J., Lo, S., Long, G., Menzies, A., Brown, L., et al (2024). The features and management of acquired resistance to PD1-based therapy in metastatic melanoma. European Journal of Cancer, 196, 113441. [More Information]

2023

• Holtkamp, L., Lo, S., Thompson, J., Spillane, A., Stretch, J., Saw, R., Shannon, K., Nieweg, O., Hong, A. (2023). Adjuvant radiotherapy after salvage surgery for melanoma recurrence in a node field following a previous lymph node dissection. Journal of Surgical Oncology, 128(1), 97-104. [More Information]
• Schoenfeldt, T., Thompson, J., Lo, S., Drzewiecki, K., Stretch, J., Saw, R., Spillane, A., Shannon, K., Uren, R., Chakera, A., Nieweg, O. (2023). ASO Visual Abstract: Prognostic Significance and Management of Sentinel Nodes in the Triangular Intermuscular Space of Patients with Melanoma. Annals of Surgical Oncology, 30(4), 2362-2363. [More Information]
• Lee, J., Ahmed, T., Maurichi, A., Di Guardo, L., Stagno, A., Warburton, L., Taylor, A., Livingstone, E., Rehman, S., Khattak, A., Lo, S., Long, G., Menzies, A., Carlino, M., et al (2023). BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. European Journal of Cancer, 179, 87-97. [More Information]
• Adegoke, N., Gide, T., Mao, Y., Quek, C., Patrick, E., Carlino, M., Lo, S., Menzies, A., Esteves Domingues Pires da Silva, I., Vergara Correa, I., Long, G., Scolyer, R., Wilmott, J. (2023). Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies. Journal for ImmunoTherapy of Cancer, 11(10). [More Information]
• Varey, A., Williams, G., Lo, S., Taing, C., Maurichi, A., Santinami, M., Scolyer, R., Thompson, J. (2023). Clinical management of melanocytic tumours of uncertain malignant potential (MelTUMPs), including melanocytomas: A systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology, 37(5), 859-870. [More Information]
• Menzies, S., Sinz, C., Menzies, M., Lo, S., Yolland, W., Lingohr, J., Razmara, M., Tschandl, P., Guitera, P., Scolyer, R., Coker, D., Collgros Totosaus, H., Gibson, M., Ho, G., Martin, A., Moloney, F., Regio Pereira, A., et al (2023). Comparison of humans versus mobile phone-powered artificial intelligence for the diagnosis and management of pigmented skin cancer in secondary care: a multicentre, prospective, diagnostic, clinical trial. The Lancet Digital Health, 5(10), e679-e691. [More Information]
• Mao, Y., Gide, T., Adegoke, N., Quek, C., Maher, N., Potter, A., Patrick, E., Saw, R., Thompson, J., Spillane, A., Shannon, K., Carlino, M., Lo, S., Menzies, A., Da Silva, I., Long, G., Scolyer, R., Wilmott, J. (2023). Cross‑platform comparison of immune signatures in immunotherapy‑treated patients with advanced melanoma using a rank‑based scoring approach. Journal of Translational Medicine, 21(Green Open Access), Article 257-16 pages. [More Information]
• El Sharouni, M., Lo, S., Varey, A., Elias, S., Witkamp, A., Sigurdsson, V., Suijkerbuijk, K., van Diest, P., van Gils, C., Blokx, W., Scolyer, R., Thompson, J. (2023). Development and validation of risk calculators for people with ""thin"" melanomas on their skin to predict the likelihood that their cancer will return: a plain language summary of publication. Future Oncology, 19(2), 97-102. [More Information]
• Weppler, A., Da Meda, L., Esteves Domingues Pires da Silva, I., Xu, W., Grignani, G., Menzies, A., Carlino, M., Long, G., Lo, S., Nordman, I., et al (2023). Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. European Journal of Cancer, 183, 109-118. [More Information]
• Lai-Kwon, J., Jacques, S., Carlino, M., Benannoune, N., Robert, C., Allayous, C., Baroudjian, B., Lebbe, C., Zimmer, L., Eroglu, Z., Lo, S., Menzies, A., Long, G., et al (2023). Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma. European Journal of Cancer, 186. [More Information]
• Li, A., Law, J., Ch'ng, S., Scolyer, R., Thompson, J., Lo, S., Varey, A. (2023). External validation in an Australian population of the EORTC-DeCOG nomogram predicting recurrence, distant metastasis and overall mortality in melanoma patients with positive sentinel lymph nodes. European Journal of Cancer, 189. [More Information]
• Iravani, A., Wallace, R., Lo, S., Galligan, A., Weppler, A., Hicks, R., Sandhu, S. (2023). FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab. Radiology, 307(3). [More Information]
• Varey, A., Thompson, J., Howle, J., Lo, S., Ch'ng, S., Carlino, M. (2023). Has the advent of modern adjuvant systemic therapy for melanoma rendered sentinel node biopsy unnecessary? European Journal of Cancer, 186, 166-171. [More Information]
• Holtkamp, L., Lo, S., Drummond, M., Thompson, J., Nieweg, O., Hong, A. (2023). Hypofractionated or Conventionally Fractionated Adjuvant Radiotherapy After Regional Lymph Node Dissection for High-Risk Stage III Melanoma. Clinical Oncology, 35(1), e85-e93. [More Information]
• Miller, J., Lo, S., Nosrati, M., Stretch, J., Spillane, A., Saw, R., Shannon, K., Nieweg, O., Ch'ng, S., Kim, K., Thompson, J., Scolyer, R., et al (2023). Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma. JAMA Network Open, 6(4), e236356. [More Information]
• Melhoranse Gouveia, B., Carlos, G., Wadell, A., Sinz, C., Ahmed, T., Lo, S., Rawson, R., Ferguson, P., Scolyer, R., Guitera, P. (2023). In vivo reflectance confocal microscopy can detect the invasive component of lentigo maligna melanoma: Prospective analysis and case–control study. Journal of the European Academy of Dermatology and Venereology, 37(7), 1293-1301. [More Information]
• Maher, N., Prosser, N., Aivazian, K., Colebatch, A., Ferguson, P., Karim, R., McKenzie, C., Rawson, R., Lo, S., Scolyer, R. (2023). Inter-rater concordance of basal cell carcinoma subtypes: influences on reporting format and opportunities for further classification modifications. Pathology, 55(6), 800-805. [More Information]
• Lee, H., Ferguson, A., Quek, C., Vergara Correa, I., Esteves Domingues Pires da Silva, I., Allen, R., Gide, T., Conway, J., Koufariotis, L., Hayward, N., Carlino, M., Menzies, A., Saw, R., Shklovskaya, E., Rizos, H., Lo, S., Scolyer, R., Long, G., Palendira, M., Wilmott, J., et al (2023). Intratumoral CD16þ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy. Clinical Cancer Research, 29(13), 2513-2524. [More Information]
• Bartula, I., Tran, A., Nowak, A., Ahmed, T., Morton, R., Burmeister, B., Dolven-Jacobsen, K., Nobes, J., Thompson, J., Fogarty, G., Lo, S., Hong, A. (2023). Longitudinal trajectory of quality of life for patients with melanoma brain metastases: A secondary analysis from a whole brain radiotherapy randomized clinical trial. Clinical and Translational Radiation Oncology. [More Information]
• El Sharouni, M., Rawson, R., Potter, A., Paver, E., Wilmott, J., Witkamp, A., Sigurdsson, V., van Diest, P., Scolyer, R., Thompson, J., Lo, S., et al (2023). Melanomas in children and adolescents: Clinicopathologic features and survival outcomes. Journal Of The American Academy Of Dermatology, 88(3), 609-616. [More Information]
• Shteinman, E., Vergara Correa, I., Rawson, R., Lo, S., Maeda, N., Koyama, K., Esteves Domingues Pires da Silva, I., Long, G., Scolyer, R., Wilmott, J., Menzies, A. (2023). Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma. Pathology, 55(5), 629-636. [More Information]
• Schoenfeldt, T., Thompson, J., Lo, S., Drzewiecki, K., Stretch, J., Saw, R., Spillane, A., Shannon, K., Uren, R., Chakera, A., Nieweg, O. (2023). Prognostic Significance and Management of Sentinel Nodes in the Triangular Intermuscular Space of Patients with Melanoma. Annals of Surgical Oncology, 30(4), 2354-2361. [More Information]
• Paver, E., Lo, S., Thompson, J., Scolyer, R., Ahmed, T., Burke, H., Saw, R., Stretch, J., Spillane, A., Shannon, K., Vergara Correa, I., et al (2023). Prognostic Significance of Incipient Ulceration in Primary Cutaneous Melanoma. JAMA Dermatology, 159(12), 1359-1367. [More Information]
• El Sharouni, M., Lo, S., Scolyer, R., van Gils, C., Thompson, J. (2023). Reply to: "Estrogen could also play a key role in the development of pediatric melanoma". Journal Of The American Academy Of Dermatology, 89(2), e97-e98. [More Information]
• Rawson, R., Vergara Correa, I., Stretch, J., Saw, R., Thompson, J., Lo, S., Scolyer, R., Busam, K. (2023). Representativeness of initial skin biopsies showing pure desmoplastic melanoma: implications for management. Pathology, 55(2), 214-222. [More Information]
• Gjorup, C., Woodford, R., Li, I., Carlino, M., Ch'ng, S., Chung, D., Hsiao, E., Lo, S., London, K., Long, G., Menzies, A., Nieweg, O., Pennington, T., Rtshiladze, M., Saw, R., Scolyer, R., Shannon, K., Spillane, A., Stretch, J., Thompson, J., Varey, A., van Akkooi, A. (2023). Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging. Annals of Surgical Oncology, 31(3), 1857-1864. [More Information]
• Blake, S., Guitera, P., Cust, A., Galea, C., Lo, S., Scolyer, R., Armstrong, B., Thompson, J., Menzies, S., Madronio, C., Morton, R., Mann, G., Watts, C. (2023). The association of dermatologist demographic density with melanoma survival in New South Wales, Australia. Australasian Journal of Dermatology, 64(3), 425-429. [More Information]
• Zhang, R., Smit, A., Espinoza, D., Allen, M., Reyes Marcelino, G., Kimlin, M., Lo, S., Sharman, A., Law, M., Kanetsky, P., Mann, G., Cust, A. (2023). Validation of self-reported sun exposure against electronic ultraviolet radiation dosimeters. International Journal of Epidemiology, 52(1), 324-328. [More Information]

2022

• Lo, S., Thompson, J. (2022). Adaptive designs for clinical trials have potential advantages, but statistical challenges lurk!. British Journal of Dermatology, 186(2), 205-206. [More Information]
• Lawless, A., Coker, D., Lo, S., Ahmed, T., Scolyer, R., Ch'ng, S., Nieweg, O., Shannon, K., Spillane, A., Stretch, J., Thompson, J., Saw, R. (2022). ASO Visual Abstract: Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-transit Melanoma Metastases. Annals of Surgical Oncology, 29(11), 7031-7032. [More Information]
• Gaetano, L., Domenico, B., Lo, S., Hamed, T., Potter, A., Thompson, J., Scolyer, R., Guitera, P., Gaetano, L., Domenico, B. (2022). Association between excision margins and local recurrence in 1407 patients with primary in situ melanomas. JAAD International, 8, 102-108. [More Information]
• Yung, A., Crouch, G., Varey, A., Lo, S., Elliott, M., Lee, J., Rawson, R., Gupta, R., Hong, A., Clark, J., Ch'ng, S. (2022). Benchmarking Survival Outcomes Following Surgical Management of pT3 and pT4 Cutaneous Squamous Cell Carcinoma of the Head and Neck. Annals of Surgical Oncology, 29(8), 5124-5138. [More Information]
• Goldinger, S., Buder-Bakhaya, K., Lo, S., Forschner, A., McKean, M., Zimmer, L., Khoo, C., Dummer, R., Eroglu, Z., Buchbinder, E., Long, G., et al (2022). Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 162, 22-33. [More Information]
• Tie, J., Cohen, J., Lahouel, K., Lo, S., Wang, Y., Kosmider, S., Wong, R., Shapiro, J., Lee, M., Harris, S., et al (2022). Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. New England Journal of Medicine, 386(24), 2261-2272. [More Information]
• Moncrieff, M., Lo, S., Scolyer, R., Heaton, M., Nobes, J., Snelling, A., Carr, M., Nessim, C., Wade, R., Peach, A., Thompson, J., et al (2022). Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases from an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease. Journal of Clinical Oncology, 40(34), 3940-3951. [More Information]
• Pennington, T., Zhao, C., Colebatch, A., Fernandez Penas, P., Guitera, P., Burke, H., Scolyer, R., Menzies, A., Carlino, M., Lo, S., Long, G., Saw, R. (2022). Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma. Australasian Journal of Dermatology, 63(2), e133-e137. [More Information]
• Lawless, A., Coker, D., Lo, S., Ahmed, T., Scolyer, R., Ch'ng, S., Nieweg, O., Shannon, K., Spillane, A., Stretch, J., Thompson, J., Saw, R. (2022). Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases. Annals of Surgical Oncology, 29(11), 7019-7028. [More Information]
• Newell, F., Johansson, P., Wilmott, J., Nones, K., Lakis, V., Pritchard, A., Lo, S., Rawson, R., Kazakoff, S., Colebatch, A., Ferguson, P., Vergara Correa, I., Long, G., Nieweg, O., Shivalingam, B., Stretch, J., Spillane, A., Saw, R., Shannon, K., Thompson, J., et al (2022). Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes. Cancer Discovery, 12(12), 2856-2879. [More Information]
• Lo, S., Ma, J., Manuguerra, M., Moreno-Betancur, M., Scolyer, R., Thompson, J. (2022). Competing risks analysis with missing cause-of-failure—penalized likelihood estimation of cause-specific Cox models. Statistical Methods in Medical Research, 31(5), 978-994. [More Information]
• Rocha, L., Vilain, R., Scolyer, R., Lo, S., Drummond, M., Star, P., Fogarty, G., Hong, A., Guitera, P. (2022). Confocal microscopy, dermoscopy, and histopathology features of atypical intraepidermal melanocytic proliferations associated with evolution to melanoma in situ. International Journal Of Dermatology, 61(2), 167-174. [More Information]
• Bagg, M., Wand, B., Cashin, A., Lee, H., Hubscher, M., Stanton, T., O'Connell, N., O'Hagan, E., Rizzo, R., Wewege, M., Lo, S., Maher, C., et al (2022). Effect of Graded Sensorimotor Retraining on Pain Intensity in Patients with Chronic Low Back Pain: A Randomized Clinical Trial. JAMA, 328(5), 430-439. [More Information]
• Hanna, S., Marinos, E., Bryan, D., Ahmed, T., Lo, S., Carlino, M., Smith, A., Cairns, G., Shannon, K., Long, G., Scolyer, R., Saw, R. (2022). Effect of the SunSafe Student Ambassador Program on the attitudes, knowledge and behaviour of Australian high-school students towards sun safety: a prospective study. Clinical and Experimental Dermatology, 47(11), 1956-1967. [More Information]
• El Sharouni, M., Scolyer, R., van Gils, C., Ch'ng, S., Nieweg, O., Pennington, T., Saw, R., Shannon, K., Spillane, A., Stretch, J., Thompson, J., Lo, S., et al (2022). Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. European Journal of Cancer, 167, 133-141. [More Information]
• Esteves Domingues Pires da Silva, I., Zakria, D., Ahmed, T., Trojanello, C., Dimitriou, F., Allayous, C., Gerard, C., Zimmer, L., Lo, S., Michielin, O., Carlino, M., Menzies, A., Long, G., et al (2022). Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. Journal for ImmunoTherapy of Cancer, 10(7). [More Information]
• Moncrieff, M., Lo, S., Scolyer, R., Heaton, M., Nobes, J., Snelling, A., Carr, M., Nessim, C., Wade, R., Peach, A., Thompson, J., et al (2022). Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study. Annals of Surgical Oncology, 29(9), 5937-5945. [More Information]
• Dimitriou, F., Lo, S., Tan, A., Emmett, L., Kapoor, R., Carlino, M., Long, G., Menzies, A. (2022). FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma. Annals of Oncology, 33(1), 99-106. [More Information]
• Seviiri, M., Scolyer, R., Bishop, D., Newton-Bishop, J., Iles, M., Lo, S., Stretch, J., Saw, R., Nieweg, O., Shannon, K., Spillane, A., Thompson, J., Long, G., et al (2022). Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting. Journal of Translational Medicine, 20(1). [More Information]
• Attrill, G., Owen, C., Ahmed, T., Vergara Correa, I., Colebatch, A., Conway, J., Nahar, K., Thompson, J., Esteves Domingues Pires da Silva, I., Carlino, M., Menzies, A., Lo, S., Palendira, M., Scolyer, R., Long, G., Wilmott, J. (2022). Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. Journal for ImmunoTherapy of Cancer, 10(6). [More Information]
• Cassidy, S., Kroeger, C., Wang, T., Mitra, S., Liu, C., Ribeiro, R., Dai, A., Lau, J., Huang, R., Masedunkas, A., Jose, S., Liu, N., McGrady, M., Lo, S., George, J., Cistulli, P., Khor, L., Kozor, R., Ugander, M., Wilcox, I., Hunyor, I., Fontana, L., et al (2022). Impact of an intensive lifestyle program on low attenuation plaque and myocardial perfusion in coronary heart disease: A randomised clinical trial protocol. Nutrition and Healthy Aging, 7(1-2), 9-22. [More Information]
• Li, A., Miin Yip, J., Choksi, H., London, K., Potter, A., Lo, S., Saw, R., Shannon, K., Esteves Domingues Pires da Silva, I., Varey, A., Menzies, A., Long, G., Shivalingam, B., Scolyer, R., Thompson, J., Ch'ng, S. (2022). Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread. Melanoma Research, 32(4), 260-268. [More Information]
• Webb, A., Ma, J., Lo, S. (2022). Penalized likelihood estimation of a mixture cure Cox model with partly interval censoring—An application to thin melanoma. Statistics in Medicine, 41(17), 3260-3280. [More Information]
• Thompson, J., Smith, A., Lo, S., Kasparian, N., Saw, R., Dieng, M., Seaman, L., Martin, L., Guitera, P., Milne, D., Schmid, H., Cust, A., Bartula, I. (2022). Protocol for the implementation of a stepped-care model to address fear of cancer recurrence in patients previously diagnosed with early-stage (0-II) melanoma. BMJ Open, 12(3), e054337-1-e054337-11. [More Information]
• Jackett, L., Satgunaseelan, L., Roper, E., Lo, S., Thompson, J., Scolyer, R. (2022). Residual melanoma in wide local excision specimens after ‘complete’ excision of primary cutaneous in situ and invasive melanomas. Pathology, 54(1), 71-78. [More Information]
• Tan, K., Lo, S., Cust, A., Wolfe, R., Mar, V. (2022). Sensitivity of two Australian melanoma risk tools to identify high-risk individuals among people presenting with their first primary melanoma. Australasian Journal of Dermatology, 63(3), 352-358. [More Information]
• Micevic, G., Lo, S., Rajan, N. (2022). Targeting the neonatal Fc receptor in pemphigus: safety first. British Journal of Dermatology, 186(3), 389-390. [More Information]
• Dieng, M., Lord, S., Turner, R., Nieweg, O., Menzies, A., Saw, R., Einstein, A., Emmett, L., Thompson, J., Lo, S., Morton, R. (2022). The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma. Annals of Surgical Oncology, 29(5), 2871-2881. [More Information]
• El Sharouni, M., Rawson, R., Sigurdsson, V., Witkamp, A., van Gils, C., Scolyer, R., Thompson, J., Van Diest, P., Lo, S. (2022). The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (≥15 mm in thickness). Journal Of The American Academy Of Dermatology, 87(2), 298-305. [More Information]
• El Sharouni, M., Scolyer, R., van Gils, C., Ch'ng, S., Nieweg, O., Pennington, T., Saw, R., Shannon, K., Spillane, A., Stretch, J., Thompson, J., Lo, S., et al (2022). Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. European Journal of Cancer, 167, 123-132. [More Information]
• Conway, J., Rawson, R., Lo, S., Ahmed, T., Vergara Correa, I., Gide, T., Attrill, G., Carlino, M., Saw, R., Thompson, J., Spillane, A., Shannon, K., Shivalingam, B., Menzies, A., Wilmott, J., Long, G., Scolyer, R., Esteves Domingues Pires da Silva, I. (2022). Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites. Journal for ImmunoTherapy of Cancer, 10(9). [More Information]

2021

• Dessinioti, C., Geller, A., Stergiopoulou, A., Dimou, N., Lo, S., Keim, U., Gershenwald, J., Haydu, L., Dummer, R., Mangana, J., Thompson, J., Scolyer, R., et al (2021). A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences*. British Journal of Dermatology, 185(1), 101-109. [More Information]
• Webster, R., Usherwood, T., Joshi, R., Saini, B., Armour, C., Critchley, S., Di Tanna, G., Galgey, S., Hespe, C., Jan, S., Krass, I., Lo, S., Patel, A., et al (2021). An electronic decision support-based complex intervention to improve management of cardiovascular risk in primary health care: a cluster randomised trial (INTEGRATE). Medical Journal of Australia, 214(9), 420-427. [More Information]
• Li, A., Vakharia, K., Lo, S., Varey, A., Carlino, M., Saw, R., Shannon, K., Howle, J., Pennington, T., Stretch, J., Nieweg, O., Spillane, A., Long, G., Menzies, A., Scolyer, R., Thompson, J., Ch'ng, S. (2021). ASO Visual Abstract: Survival Outcomes of Salvage Metastasectomy after Failure of Modern-Era Systemic Therapy for Melanoma. Annals of Surgical Oncology, 28, 597-598. [More Information]
• El Sharouni, M., Aivazian, K., Witkamp, A., Sigurdsson, V., van Gils, C., Scolyer, R., Thompson, J., van Diest, P., Lo, S. (2021). Association of Histologic Regression with a Favorable Outcome in Patients with Stage 1 and Stage 2 Cutaneous Melanoma. JAMA Dermatology, 157(2), 166-173. [More Information]
• Crouch, G., Sinha, S., Lo, S., Saw, R., Lee, K., Stretch, J., Shannon, K., Guitera, P., Scolyer, R., Thompson, J., Ch'ng, S. (2021). Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. European Journal of Surgical Oncology, 47(5), 1145-1151. [More Information]
• Owen, C., Bai, X., Quah, T., Lo, S., Allayous, C., Callaghan, S., Martínez-Vila, C., Wallace, R., Bhave, P., Reijers, I., et al (2021). Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma. Annals of Oncology, 32(7), 917-925. [More Information]
• El Sharouni, M., Ahmed, T., Varey, A., Elias, S., Witkamp, A., Sigurdsson, V., Suijkerbuijk, K., van Diest, P., Scolyer, R., van Gils, C., Thompson, J., Lo, S., et al (2021). Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas. Journal of Clinical Oncology, 39(11), 1243-1252. [More Information]
• Holland, E., Lo, S., Kelly, B., Schmid, H., Cust, A., Palmer, J., Drummond, M., Hayward, N., Pritchard, A., Mann, G. (2021). FRAMe: Familial Risk Assessment of Melanoma—a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma. Familial Cancer, 20(3), 231-239. [More Information]
• Aivazian, K., Ahmed, T., El Sharouni, M., Stretch, J., Saw, R., Spillane, A., Shannon, K., Ch'ng, S., Nieweg, O., Thompson, J., Lo, S., Scolyer, R. (2021). Histological regression in melanoma: impact on sentinel lymph node status and survival. Modern Pathology, 34(11), 1999-2008. [More Information]
• Dearden, H., Au, L., Wang, D., Zimmer, L., Eroglu, Z., Smith, J., Cuvietto, M., Khoo, C., Atkinson, V., Lo, S., Long, G., Carlino, M., Menzies, A., et al (2021). Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. European Journal of Cancer, 153, 168-178. [More Information]
• Smit, A., Allen, M., Beswick, B., Butow, P., Dawkins, H., Dobbinson, S., Dunlop, K., Espinoza, D., Fenton, G., Kanetsky, P., Kirk, J., Lo, S., Mann, G., Reyes Marcelino, G., Morton, R., Newson, A., Trevena, L., Cust, A., et al (2021). Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trial. Genetics in Medicine, 23(12), 2394-2403. [More Information]
• Esteves Domingues Pires da Silva, I., Ahmed, T., Reijers, I., Weppler, A., Betof Warner, A., Patrinely, J., Serra-Bellver, P., Allayous, C., Mangana, J., Nguyen, K., Carlino, M., Lo, S., Menzies, A., Long, G., et al (2021). Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. The Lancet Oncology, 22(6), 836-847. [More Information]
• Da Silva, I., Ahmed, T., Reijers, I., Warner, A., Patrinely, J., Serra-Bellver, P., Allayous, C., Mangana, J., Zimmer, L., Trojaniello, C., Carlino, M., Lo, S., Menzies, A., Long, G., et al (2021). Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply. The Lancet Oncology, 22(8), e343-e344. [More Information]
• Collgros Totosaus, H., Rodriguez-Lomba, E., Regio Pereira, A., Lo, S., Scolyer, R., Guitera, P. (2021). Lentiginous melanoma (lentigo maligna and lentigo maligna melanoma) in Australia: clinicopathological characteristics, management and recurrence rates after 10-year follow-up at a tertiary centre. Journal of the European Academy of Dermatology and Venereology, 35(6), 1315-1322. [More Information]
• Star, P., Rawson, R., Drummond, M., Lo, S., Scolyer, R., Guitera, P. (2021). Lentigo maligna: defining margins and predictors of recurrence utilizing clinical, dermoscopic, confocal microscopy and histopathology features. Journal of the European Academy of Dermatology and Venereology, 35(9), 1811-1820. [More Information]
• Waldstein, C., Wang, T., Lo, S., Shivalingam, B., Fogarty, G., Carlino, M., Menzies, A., Long, G., Hong, A. (2021). Melanoma brain metastases: The outcome of whole brain radiation therapy in the era of effective systemic therapy. Therapeutic Radiology and Oncology, 5(3), 11. [More Information]
• Hollestein, L., Lo, S., Leonardi-Bee, J., Rosset, S., Shomron, N., Couturier, D., Gran, S. (2021). MULTIPLE ways to correct for MULTIPLE comparisons in MULTIPLE types of studies. British Journal of Dermatology, 185(6), 1081-1083. [More Information]
• Menzies, A., Amaria, R., Rozeman, E., Huang, A., Tetzlaff, M., van de Wiel, B., Lo, S., Tarhini, A., Burton, E., Pennington, T., Saw, R., Spillane, A., Scolyer, R., Long, G., et al (2021). Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nature Medicine, 27(2), 301-309. [More Information]
• Rawson, R., Adhikari, C., Bierman, C., Lo, S., Shklovskaya, E., Rozeman, E., Menzies, A., van Akkooi, A., Shannon, K., Gonzalez, M., Guminski, A., Stretch, J., Nieweg, O., Ch'ng, S., Rizos, H., Saw, R., Spillane, A., Wilmott, J., Long, G., Scolyer, R., et al (2021). Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. Annals of Oncology, 32(6), 766-777. [More Information]
• El Sharouni, M., Ahmed, T., Witkamp, A., Sigurdsson, V., van Gils, C., Nieweg, O., Scolyer, R., Thompson, J., van Diest, P., Lo, S. (2021). Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data. British Journal of Surgery, 108(5), 550-553. [More Information]
• El Sharouni, M., Varey, A., Witkamp, A., Ahmed, T., Sigurdsson, V., van Diest, P., Scolyer, R., Thompson, J., Lo, S., van Gils, C. (2021). Predicting sentinel node positivity in patients with melanoma: external validation of a risk-prediction calculator (the Melanoma Institute Australia nomogram) using a large European population-based patient cohort*. British Journal of Dermatology, 185(2), 412-418. [More Information]
• Tie, J., Cohen, J., Lo, S., Wang, Y., Li, L., Christie, M., Lee, M., Wong, R., Kosmider, S., Skinner, I., Tomasetti, C., et al (2021). Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. International Journal of Cancer, 148(4), 1014-1026. [More Information]
• Ch'ng, S., Uyulmaz, S., Carlino, M., Pennington, T., Shannon, K., Rtshiladze, M., Stretch, J., Nieweg, O., Varey, A., Hsiao, E., Kapoor, R., Esteves Domingues Pires da Silva, I., Lo, S., Spillane, A., Scolyer, R., Long, G., Hong, A., Saw, R., Thompson, J., Menzies, A. (2021). Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. European Journal of Cancer, 153, 8-15. [More Information]
• Hepner, A., Atkinson, V., Larkin, J., Burrell, R., Carlino, M., Johnson, D., Zimmer, L., Tsai, K., Klein, O., Lo, S., Pallan, L., Esteves Domingues Pires da Silva, I., Long, G., Menzies, A., et al (2021). Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti–PD-1 therapy. European Journal of Cancer, 153, 213-222. [More Information]
• Choi, S., Hong, A., Wang, T., Lo, S., Chen, B., Silva, I., Kapoor, R., Hsiao, E., Fogarty, G., Carlino, M., Menzies, A., Long, G., et al (2021). Risk of radiation necrosis after stereotactic radiosurgery for melanoma brain metastasis by anatomical location. Strahlentherapie und Onkologie, 197(12), 1104-1112. [More Information]
• El Sharouni, M., Stodell, M., Ahmed, T., Suijkerbuijk, K., Cust, A., Witkamp, A., Sigurdsson, V., van Diest, P., Scolyer, R., Thompson, J., Lo, S., et al (2021). Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. Annals of Oncology, 32(3), 375-383. [More Information]
• Hanna, S., Lo, S., Saw, R. (2021). Surgical excision margins in primary cutaneous melanoma: A systematic review and meta-analysis. European Journal of Surgical Oncology, 47(7), 1558-1574. [More Information]
• Li, A., Vakharia, K., Lo, S., Varey, A., Carlino, M., Saw, R., Shannon, K., Howle, J., Pennington, T., Stretch, J., Nieweg, O., Spillane, A., Long, G., Menzies, A., Scolyer, R., Thompson, J., Ch'ng, S. (2021). Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma. Annals of Surgical Oncology, 28(11), 6109-6123. [More Information]
• Bagg, M., Lo, S., Cashin, A., Herbert, R., O'Connell, N., Lee, H., Hubscher, M., Wand, B., O'Hagan, E., Rizzo, R., Maher, C., et al (2021). The RESOLVE Trial for people with chronic low back pain: statistical analysis plan. Brazilian Journal of Physical Therapy, 25(1), 103-111. [More Information]
• Muir, C., Clifton-Bligh, R., Long, G., Scolyer, R., Lo, S., Carlino, M., Tsang, V., Menzies, A. (2021). Thyroid Immune-related Adverse Events following Immune Checkpoint Inhibitor Treatment. Journal of Clinical Endocrinology and Metabolism, 106(9), E3704-E3713. [More Information]
• Garg, M., Couturier, D., Nsengimana, J., Fonseca, N., Wongchenko, M., Yan, Y., Lauss, M., Jönsson, G., Newton-Bishop, J., Parkinson, C., Vergara Correa, I., Lo, S., Wilmott, J., Thompson, J., Long, G., Scolyer, R., et al (2021). Tumour gene expression signature in primary melanoma predicts long-term outcomes. Nature Communications, 12(1), 1137. [More Information]

2020

• Gonzalez, M., Menzies, A., Pennington, T., Saw, R., Spillane, A., Stretch, J., Shannon, K., Ch'ng, S., Nieweg, O., Rojas, M., Lo, S., Scolyer, R., Long, G., et al (2020). A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study. Journal of Clinical Oncology, 38(15), TPS10088. [More Information]
• Cust, A., Badcock, C., Smith, J., Thomas, N., Haydu, L., Armstrong, B., Law, M., Thompson, J., Kanetsky, P., Begg, C., Kricker, A., Lo, S., et al (2020). A risk prediction model for the development of subsequent primary melanoma in a population-based cohort. British Journal of Dermatology, 182(5), 1148-1157. [More Information]
• Ipenburg, N., Nieweg, O., Lo, S. (2020). Author response to: Comment on: External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. British Journal of Surgery, 107(5), 616. [More Information]
• Dieng, M., Morton, R., Costa, D., Butow, P., Menzies, S., Lo, S., Mann, G., Cust, A., Kasparian, N. (2020). Benefits of a brief psychological intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: 12-month follow-up results of a randomized controlled trial. Asia-Pacific Journal of Clinical Oncology, 182(4), 860-868. [More Information]
• Nahar, K., Rawson, R., Ahmed, T., Tattersall, S., Sandanayake, N., Kiely, C., Lo, S., Carlino, M., Palendira, M., Scolyer, R., Long, G., Menzies, A. (2020). Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. Journal for ImmunoTherapy of Cancer, 8(2), 1-12. [More Information]
• Mason, R., Dearden, H., Nguyen, B., Soon, J., Smith, J., Randhawa, M., Mant, A., Warburton, L., Lo, S., Meniawy, T., Guminski, A., Long, G., Carlino, M., Menzies, A., et al (2020). Combined ipilimumab and nivolumab first-line and after BRAF targeted therapy in advanced melanoma. Pigment Cell & Melanoma Research, 33(2), 358-365. [More Information]
• Bagge, R., Kicinski, M., Faries, M., Gyorki, D., Isaksson, K., Katsarelias, D., Lo, S., Moncrieff, M., Spillane, A., Suciu, S., et al (2020). Comment on "factors affecting sentinel node metastasis in thin (T1) cutaneous melanomas: Development and external validation of a predictive nomogram". Journal of Clinical Oncology, 38(27), 3233-3234. [More Information]
• Haydu, L., Lo, S., McQuade, J., Amaria, R., Wargo, J., Ross, M., Cormier, J., Lucci, A., Lee, J., Ferguson, S., Saw, R., Spillane, A., Shannon, K., Stretch, J., Carlino, M., Menzies, A., Long, G., Scolyer, R., Thompson, J., et al (2020). Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. Journal of Clinical Oncology, 38(13), 1429-1441. [More Information]
• Menzies, S., Liyanarachchi, S., Coates, E., Smith, A., Cooke-Yarborough, C., Lo, S., Armstrong, B., Scolyer, R., Guitera, P. (2020). Estimated risk of progression of lentigo maligna to lentigo maligna melanoma. Melanoma Research, 30(2), 193-197. [More Information]
• Tetzlaff, M., Adhikari, C., Lo, S., Rawson, R., Amaria, R., Menzies, A., Wilmott, J., Ferguson, P., Ross, M., Spillane, A., Saw, R., Long, G., Scolyer, R., et al (2020). Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Annals of Oncology, 31(11), 1569-1579. [More Information]
• Lo, S., Ma, J., Scolyer, R., Haydu, L., Stretch, J., Saw, R., Nieweg, O., Shannon, K., Spillane, A., Ch'ng, S., Mann, G., Thompson, J., Varey, A., et al (2020). Improved risk prediction calculator for sentinel node positivity in patients with melanoma: The melanoma institute australia nomogram. Journal of Clinical Oncology, 38(24), 2719-2727. [More Information]
• Owen, C., Shoushtari, A., Chauhan, D., Palmieri, D., Lee, B., Rohaan, M., Mangana, J., Atkinson, V., Zaman, F., Young, A., Hersey, P., Lo, S., Carlino, M., Menzies, A., Long, G., et al (2020). Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. Annals of Oncology, 31(8), 1075-1082. [More Information]
• Varey, A., Lo, S., Scolyer, R., Thompson, J. (2020). Predicting sentinel node status in patients with melanoma: Does gene expression profiling improve accuracy? JCO Precision Oncology, 4, 990-991. [More Information]
• Harris, C., Lo, S., Ahmed, T., Scolyer, R., Ferguson, P., Karim, R., Lam, T., Lee, K., Shannon, K., Spillane, A., Stretch, J., Thompson, J., Saw, R. (2020). Primary dermal melanoma: clinical behaviour, prognosis and treatment. European Journal of Surgical Oncology, 46(11), 2131-2139. [More Information]
• Kashani-Sabet, M., Miller, J., Lo, S., Nosrati, M., Stretch, J., Shannon, K., Spillane, A., Saw, R., Cleaver, J., Kim, K., Thompson, J., Scolyer, R., et al (2020). Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system. Cancer, 126(21), 4717-4725. [More Information]
• Thompson, J., London, K., Uren, R., Pennington, T., Saw, R., Lo, S. (2020). Same-day or next-day sentinel node biopsy after lymphoscintigraphy for melanoma using 99mTc-labelled antimony sulphide colloid. British Journal of Surgery, 107(13), 1773-1779. [More Information]
• Esteves Domingues Pires da Silva, I., Lo, S., Quek, C., Gonzalez, M., Carlino, M., Long, G., Menzies, A. (2020). Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. Cancer, 126(1), 86-97. [More Information]
• Lo, S., Smit, A., Espinoza, D., Cust, A. (2020). The Melanoma Genomics Managing Your Risk Study randomised controlled trial: statistical analysis plan. Trials, 21(1), 594. [More Information]
• Niebling, M., Haydu, L., Lo, S., Rawson, R., Lamboo, L., Stollman, J., Karim, R., Thompson, J., Scolyer, R. (2020). The prognostic significance of microsatellites in cutaneous melanoma. Modern Pathology, 33(7), 1369-1379. [More Information]
• Edwards, J., Ferguson, P., Lo, S., Da Silva, I., Colebatch, A., Lee, H., Saw, R., Thompson, J., Menzies, A., Long, G., Scolyer, R., Palendira, M., Wilmott, J., et al (2020). Tumor mutation burden and structural chromosomal aberrations are not associated with T-cell density or patient survival in acral, mucosal, and cutaneous melanomas. Cancer Immunology Research, 8(11), 1346-1353. [More Information]

2019

• Hong, A., Fogarty, G., Dolven-Jacobsen, K., Burmeister, B., Lo, S., Haydu, L., Vardy, J., Nowak, A., Dhillon, H., Ahmed, T., Shivalingam, B., Long, G., Menzies, A., Hruby, G., Paton, E., Steel, V., Williams, N., Scolyer, R., Morton, R., Thompson, J., et al (2019). Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. Journal of Clinical Oncology, 37(33), 3132-3141. [More Information]
• Friedman, E., Dodds, T., Lo, S., Ferguson, P., Beck, M., Saw, R., Stretch, J., Lee, K., Nieweg, O., Spillane, A., Scolyer, R., Thompson, J. (2019). Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision Specimens. Annals of Surgical Oncology, 26(1), 25-32. [More Information]
• Dessinioti, C., Dimou, N., Geller, A., Stergiopoulou, A., Lo, S., Keim, U., Gershenwald, J., Haydu, L., Ribero, S., Quaglino, P., Thompson, J., Scolyer, R., et al (2019). Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers. Journal of the National Cancer Institute, 111(12), 1314-1322. [More Information]
• Gide, T., Quek, C., Menzies, A., Tasker, A., Shang, P., Holst, J., Madore, J., Lim, S., Wongchenko, M., Lo, S., Carlino, M., Guminski, A., Saw, R., Pang, A., McGuire, H., Palendira, M., Thompson, J., Rizos, H., Da Silva, I., Batten, M., Scolyer, R., Long, G., Wilmott, J., et al (2019). Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell, 35(2), 238-255.e6. [More Information]
• Traeger, A., Lee, H., Hubscher, M., Skinner, I., Moseley, L., Nicholas, M., Henschke, N., Refshauge, K., Blyth, F., Main, C., Lo, S., et al (2019). Effect of Intensive Patient Education vs Placebo Patient Education on Outcomes in Patients With Acute Low Back Pain: A Randomized Clinical Trial. JAMA Neurology, 76(2), 161-169. [More Information]
• Abdulla, F., Saad, A., Sadat-Ali, M., Alkhamis, F., Alkawaja, H., Lo, S. (2019). Effects of pulsed low-frequency magnetic field therapy on pain intensity in patients with musculoskeletal chronic low back pain: study protocol for a randomised double-blind placebo-controlled trial. BMJ Open, 9(6), 1-9. [More Information]
• Ipenburg, N., Nieweg, O., Ahmed, T., van Doorn, R., Scolyer, R., Long, G., Thompson, J., Lo, S. (2019). External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. British Journal of Surgery, 106(10), 1319-1326. [More Information]
• Lo, S., Scolyer, R., Thompson, J., Stodell, M. (2019). In reply to Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma. Journal Of The American Academy Of Dermatology, 80(1), e21-e22. [More Information]
• Da Silva, I., Glitza, I., Haydu, L., Johnpulle, R., Banks, P., Grass, G., Goldinger, S., Smith, J., Everett, A., Koelblinger, P., Guminski, A., Kapoor, R., Carlino, M., Wang, T., Lo, S., Hong, A., Long, G., Menzies, A., et al (2019). Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell & Melanoma Research, 32(4), 553-563. [More Information]
• Long, G., Saw, R., Lo, S., Nieweg, O., Shannon, K., Gonzales, M., Guminski, A., Lee, J., Lee, H., Ferguson, P., Rawson, R., Wilmott, J., Thompson, J., Kefford, R., Ch'ng, S., Stretch, J., Rizos, H., Spillane, A., Scolyer, R., Menzies, A., et al (2019). Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. The Lancet Oncology, 20(7), 961-971. [More Information]
• Amaria, R., Menzies, A., Burton, E., Scolyer, R., Tetzlaff, M., Antdbacka, R., Ariyan, C., Bassett, R., Carter, B., Daud, A., Hong, A., Lo, S., Rizos, H., Saw, R., Thompson, J., Spillane, A., Long, G., et al (2019). Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. The Lancet Oncology, 20(7), e378-e389. [More Information]
• Kirtschig, G., Lo, S., Batchelor, J. (2019). Pragmatic trials: lab meets bedside. British Journal of Dermatology, 181(3), 431-433. [More Information]
• Lee, J., Saw, R., Thompson, J., Lo, S., Spillane, A., Shannon, K., Stretch, J., Howle, J., Menzies, A., Carlino, M., Long, G., Scolyer, R., et al (2019). Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. Annals of Oncology, 30(5), 815-822. [More Information]
• Dodds, T., Wilmott, J., Jackett, L., Lo, S., Long, G., Thompson, J., Scolyer, R. (2019). Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. Pathology, 51(1), 39-45. [More Information]
• Thompson, J., Lo, S., Scolyer, R. (2019). Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck. JAMA Dermatology, 155(4), 502. [More Information]
• Friedman, E., Moncrieff, M., Lo, S., Scolyer, R., Thompson, J. (2019). Sentinel lymph node biopsy remains the most accurate method of obtaining staging and prognostic information for patients with primary cutaneous melanomas. Australasian Journal of Dermatology, 60(1), 75-76. [More Information]
• Chakera, A., Quinn, M., Lo, S., Drummond, M., Haydu, L., Bond, J., Stretch, J., Saw, R., Lee, K., McCarthy, W., Scolyer, R., Thompson, J. (2019). Subungual Melanoma of the Hand. Annals of Surgical Oncology, 26(4), 1035-1043. [More Information]
• Lai-Kwon, J., Khoo, C., Lo, S., Milne, D., Mohamed, M., Raleigh, J., Smith, K., Lisy, K., Sandhu, S., Jefford, M. (2019). The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. Journal of Cancer Survivorship, 13(4), 503-511. [More Information]
• Lo, S., Hong, A., Haydu, L., Ahmed, T., Paton, E., Steel, V., Hruby, G., Tran, A., Morton, R., Nowak, A., Vardy, J., Dhillon, H., Scolyer, R., Thompson, J., Fogarty, G., et al (2019). Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan. Trials, 20(1), 1-13. [More Information]
• Newell, F., Kong, Y., Wilmott, J., Johansson, P., Ferguson, P., Cui, C., Li, Z., Kazakoff, S., Burke, H., Dodds, T., Tembe, V., Shang, P., Lo, S., Rawson, R., Long, G., Spillane, A., Shannon, K., Thompson, J., Saw, R., Mann, G., Scolyer, R., et al (2019). Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications, 10(1), 1-15. [More Information]

2018

• Moncrieff, M., Gyorki, D., Saw, R., Spillane, A., Peach, H., Oudit, D., Geh, J., Dziewulski, P., Wilson, E., Matteucci, P., et al (2018). 1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study. Annals of Surgical Oncology, 25(9), 2541-2549. [More Information]
• Thompson, J., Scolyer, R., Lo, S. (2018). ASO Author Reflections: Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas. Annals of Surgical Oncology, 25, S918-S919. [More Information]
• Lee, J., Long, G., Menzies, A., Lo, S., Guminski, A., Whitbourne, K., Peranec, M., Scolyer, R., Kefford, R., Rizos, H., Carlino, M. (2018). Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. JAMA Oncology, 4(5), 717-721. [More Information]
• Long, G., Atkinson, V., Lo, S., Sandhu, S., Guminski, A., Brown, M., Wilmott, J., Edwards, J., Gonzalez, M., Scolyer, R., Menzies, A., et al (2018). Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. The Lancet Oncology, 19(5), 672-681. [More Information]
• Cullen, P., Clapham, K., Lo, S., Rogers, K., Hunter, K., Treacy, R., Porykali, B., Keay, L., Senserrick, T., Ivers, R. (2018). Communities driving change: Evaluation of an Aboriginal driver licensing programme in Australia. Health Promotion International, 33(6), 925-937. [More Information]
• Tan, A., Emmett, L., Lo, S., Liu, V., Kapoor, R., Carlino, M., Guminski, A., Long, G., Menzies, A. (2018). FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Annals of Oncology, 29(10), 2115-2120. [More Information]
• Lo, S., Scolyer, R., Thompson, J. (2018). Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8 mm Separates Higher-Risk and Lower-Risk Tumors. Annals of Surgical Oncology, 25(4), 894-902. [More Information]
• Lee, J., Lyle, M., Menzies, A., Chan, M., Lo, S., Clements, A., Carlino, M., Kefford, R., Long, G. (2018). Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma. Pigment Cell & Melanoma Research, 31(3), 404-410. [More Information]
• Dodds, T., Lo, S., Jackett, L., Nieweg, O., Thompson, J., Scolyer, R. (2018). Prognostic Significance of Periadnexal Extension in Cutaneous Melanoma and its Implications for Pathologic Reporting and Staging. The American Journal of Surgical Pathology, 42(3), 359-366. [More Information]
• Martinage, G., Hong, A., Fay, M., Thachil, T., Roos, D., Williams, N., Lo, S., Fogarty, G. (2018). Quality assurance analysis of hippocampal avoidance in a melanoma whole brain radiotherapy randomized trial shows good compliance. Radiation Oncology, 13(1), 132. [More Information]
• Wang, Y., Gallagher, M., Li, Q., Lo, S., Cass, A., Finfer, S., Myburgh, J., Bouman, C., Faulhaber-Walter, R., Kellum, J., et al (2018). Renal replacement therapy intensity for acute kidney injury and recovery to dialysis independence: A systematic review and individual patient data meta-analysis. Nephrology Dialysis Transplantation, 33(6), 1017-1024. [More Information]
• Lo, S., Sandhu, S. (2018). Reply to M. Horiguchi et al. Journal of Clinical Oncology, 36(7), 722-723. [More Information]
• Schmidt, S., Lo, S., Hollestein, L. (2018). Research Techniques Made Simple: Sample Size Estimation and Power Calculation. Journal of Investigative Dermatology, 138(8), 1678-1682. [More Information]
• Mitchell, E., Lau, P., Khoo, C., Liew, D., Leung, J., Liu, B., Rischin, A., Frauman, A., Kee, D., Smith, K., Lo, S., et al (2018). Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. European Journal of Cancer, 105, 88-102. [More Information]
• Tio, M., Wang, X., Carlino, M., Shivalingam, B., Fogarty, G., Guminski, A., Lo, S., Hong, A., Menzies, A., Long, G. (2018). Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. Pigment Cell & Melanoma Research, 31(4), 509-515. [More Information]
• Hollestein, L., Leonardi-Bee, J., Lo, S., Rosset, S., Shomron, N. (2018). The ABC of reporting statistical analyses in the BJD: Always Be Clear. British Journal of Dermatology, 179(1), 3-5. [More Information]
• Smit, A., Newson, A., Morton, R., Kimlin, M., Keogh, L., Law, M., Kirk, J., Dobbinson, S., Kanetsky, P., Fenton, G., Butow, P., Trevena, L., Lo, S., Savard, J., Mann, G., Cust, A., et al (2018). The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviors. Contemporary Clinical Trials, 70, 106-116. [More Information]

2017

• Itchins, M., Ascierto, P., Menzies, A., Oatley, M., Lo, S., Douraghi-Zadeh, D., Harrington, T., Maher, R., Grimaldi, A., Guminski, A. (2017). A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy. Melanoma Research, 27(3), 243-250. [More Information]
• Traeger, A., Skinner, I., Hubscher, M., Lee, H., Moseley, G., Nicholas, M., Henschke, N., Refshauge, K., Blyth, F., Main, C., Lo, S., et al (2017). A randomized, placebo-controlled trial of patient education for acute low back pain (PREVENT Trial): statistical analysis plan. Brazilian Journal of Physical Therapy, 21(3), 219-223. [More Information]
• Jardine, M., Zuo, L., Gray, N., de Zoysa, J., Chan, C., Gallagher, M., Monaghan, H., Grieve, S., Puranik, R., Lin, H., Howard, K., Lo, S., Perkovic, V., et al (2017). A Trial of Extending Hemodialysis Hours and Quality of Life. Journal of the American Society of Nephrology, 28(6), 1898-1911. [More Information]
• Heritier, S., Lloyd, C., Lo, S. (2017). Accurate p-values for adaptive designs with binary endpoints. Statistics in Medicine, 36(17), 2643-2655. [More Information]
• Rocha, L., Menzies, S., Lo, S., Avramidis, M., Khoury, R., Jackett, L., Guitera, P. (2017). Analysis of an electrical impedance spectroscopy system in short-term digital dermoscopy imaging of melanocytic lesions. British Journal of Dermatology, 177(5), 1432-1438. [More Information]
• Lee, J., Long, G., Boyd, S., Lo, S., Menzies, A., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R., Mann, G., Kefford, R., Carlino, M., Rizos, H. (2017). Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Annals of Oncology, 28(5), 1130-1136. [More Information]
• Haydu, L., Scolyer, R., Lo, S., Quinn, M., Saw, R., Shannon, K., Spillane, A., Stretch, J., McCarthy, W., Thompson, J. (2017). Conditional survival: an assessment of the prognosis of patients at time points after initial diagnosis and treatment of locoregional melanoma metastasis. Journal of Clinical Oncology, 35(15), 1721-1729. [More Information]
• Vilain, R., Menzies, A., Wilmott, J., Kakavand, H., Madore, J., Guminski, A., Liniker, E., Kong, B., Cooper, A., Howle, J., Saw, R., Jakrot, V., Lo, S., Thompson, J., Carlino, M., Kefford, R., Long, G., Scolyer, R. (2017). Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in Melanoma. Clinical Cancer Research, 23(17), 5024-5033. [More Information]
• Parakh, S., Park, J., Mendis, S., Rai, R., Xu, W., Lo, S., Drummond, M., Rowe, C., Wong, A., McArthur, G., Guminski, A., Kefford, R., Long, G., Menzies, A., Carlino, M., et al (2017). Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. British Journal of Cancer, 116(12), 1558-1563. [More Information]
• Crookes, T., Scolyer, R., Lo, S., Drummond, M., Spillane, A. (2017). Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients. Annals of Surgical Oncology, 24(5), 1378-1385. [More Information]
• Fealy, N., Aitken, L., du Toit, E., Lo, S., Baldwin, I. (2017). Faster Blood Flow Rate Does Not Improve Circuit Life in Continuous Renal Replacement Therapy: A Randomized Controlled Trial. Critical Care Medicine, 45(10), e1018-e1025. [More Information]
• Gleeson, M., Sherrington, C., Lo, S., Auld, R., Keay, L. (2017). Impact of the Alexander technique on well-being: a randomised controlled trial involving older adults with visual impairment. Clinical and Experimental Optometry, 100(6), 633-641. [More Information]
• Maher, N., Blumetti, T., Gomes, E., Cheng, H., Satgunaseelan, L., Lo, S., Rezze, G., Scolyer, R., Guitera, P. (2017). Melanoma diagnosis may be a pitfall for optical coherence tomography assessment of equivocal amelanotic or hypomelanotic skin lesions. British Journal of Dermatology, 177(2), 574-577. [More Information]
• Choong, E., Lo, S., Drummond, M., Fogarty, G., Menzies, A., Guminski, A., Shivalingam, B., Clarke, K., Long, G., Hong, A. (2017). Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. European Journal of Cancer, 75, 169-178. [More Information]
• Paul, S., Harvey, L., Carroll, T., Li, Q., Boufous, S., Priddis, A., Tiedemann, A., Clemson, L., Lord, S., Muecke, S., Sherrington, C., et al (2017). Trends in fall-related ambulance use and hospitalisation among older adults in NSW, 2006-2013: a retrospective population-based study. Public Health Research and Practice, 27(4), 1-7. [More Information]
• Rawson, R., Johansson, P., Hayward, N., Waddell, N., Patch, A., Lo, S., Pearson, J., Thompson, J., Mann, G., Scolyer, R., Wilmott, J. (2017). Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas. Laboratory Investigation, 97(2), 130-145. [More Information]

2016

• Heritier, S., Morgan-Bouniol, C., Lo, S., Gautier, S., Voisard, J. (2016). A single pivotal adaptive trial in infants with proliferating hemangioma: Rationale, design challenges, experience and recommendations. In Not known (Eds.), Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects, (pp. 453-482). TBC. [More Information]
• Cheng, H., Lo, S., Scolyer, R., Meekings, A., Carlos Minano, G., Guitera, P. (2016). Accuracy of optical coherence tomography for the diagnosis of superficial basal cell carcinoma: a prospective, consecutive, cohort study of 168 cases. British Journal of Dermatology, 175(6), 1290-1300. [More Information]
• Liniker, E., Menzies, A., Kong, B., Cooper, A., Ramanujam, S., Lo, S., Kefford, R., Fogarty, G., Guminski, A., Wang, T., Carlino, M., Hong, A., Long, G. (2016). Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. OncoImmunology, 5(9), 1-7. [More Information]
• Hayek, A., Joshi, R., Usherwood, T., Webster, R., Kaur, B., Saini, B., Armour, C., Krass, I., Laba, T., Reid, C., Hersch, F., Jan, S., Lo, S., Peiris, D., Rodgers, A., Patel, A., et al (2016). An integrated general practice and pharmacy-based intervention to promote the use of appropriate preventive medications among individuals at high cardiovascular disease risk: Protocol for a cluster randomized controlled trial. Implementation Science, 11(1), 1-9. [More Information]
• Ge, L., Vilain, R., Lo, S., Aivazian, K., Scolyer, R., Thompson, J. (2016). Breslow Thickness Measurements of Melanomas Around American Joint Committee on Cancer Staging Cut-Off Points: Imprecision and Terminal Digit Bias Have Important Implications for Staging and Patient Management. Annals of Surgical Oncology, 23(8), 2658-2663. [More Information]
• Fogarty, G., Hong, A., Gondi, V., Burmeister, B., Dolven Jacobsen, K., Lo, S., Paton, E., Shivalingam, B., Thompson, J. (2016). Debate: adjuvant whole brain radiotherapy or not? More data is the wiser choice. BMC Cancer, 16(1), 1-5. [More Information]
• Ivers, R., Sakashita, C., Senserrick, T., Elkington, J., Lo, S., Boufous, S., de Rome, L. (2016). Does an on-road motorcycle coaching program reduce crashes in novice riders? A randomised control trial. Accident Analysis and Prevention, 86, 40-46. [More Information]
• Bellomo, R., Martensson, J., Kaukonen, K., Lo, S., Gallagher, M., Cass, A., Myburgh, J., Finfer, S. (2016). Epidemiology of RBC Transfusions in Patients With Severe Acute Kidney Injury: Analysis From the Randomized Evaluation of Normal Versus Augmented Level Study. Critical Care Medicine, 44(5), 892-900. [More Information]
• Bellomo, R., Martensson, J., Lo, S., Kaukonen, K., Cass, A., Gallagher, M. (2016). Femoral Access and Delivery of Continuous Renal Replacement Therapy Dose. Blood Purification, 41(1-3), 11-17. [More Information]
• Zheng, D., Arima, H., Sato, S., Gasparrini, A., Heeley, E., Delcourt, C., Lo, S., Huang, Y., Wang, J., Stapf, C., Chalmers, J., Anderson, C., et al (2016). Low Ambient Temperature and Intracerebral Hemorrhage: The INTERACT2 Study. PloS One, 11(2), 1-14. [More Information]

2015

• Gattas, D., Rajbhandari, D., Bradford, C., Buhr, H., Lo, S., Bellomo, R. (2015). A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults. Critical Care Medicine, 43(8), 1622-1629. [More Information]
• Coxon, K., Chevalier, A., Lo, S., Ivers, R., Brown, J., Keay, L. (2015). Behind the Wheel: Confidence and Naturalistic Measures of Driving Exposure Among Older Drivers. Transportation Research Record, 2516, 35-43. [More Information]
• Coxon, K., Chevalier, A., Lo, S., Ivers, R., Brown, J., Keay, L. (2015). Behind the Wheel: Predictors of Driving Exposure in Older Drivers. Journal of the American Geriatrics Society, 63(6), 1137-1145. [More Information]
• Gleeson, M., Sherrington, C., Lo, S., Keay, L. (2015). Can the Alexander Technique improve balance and mobility in older adults with visual impairments? A randomized controlled trial. Clinical Rehabilitation, 29(3), 244-260. [More Information]
• Menzies, A., Wilmott, J., Drummond, M., Lo, S., Lyle, M., Chan, M., Thompson, J., Guminski, A., Carlino, M., Scolyer, R., Kefford, R., Long, G. (2015). Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer, 121(21), 3826-3835. [More Information]
• Peiris, D., Usherwood, T., Panaretto, K., Harris, M., Hunt, J., Redfern, J., Zwar, N., Colagiuri, S., Hayman, N., Lo, S., Patel, B., Lyford, M., MacMahon, S., Neal, B., Sullivan, D., Patel, A., et al (2015). Effect of a computer-guided, quality improvement program for cardiovascular disease risk management in primary health care: the treatment of cardiovascular risk using electronic decision support cluster-randomized trial. Circulation: Cardiovascular Quality and Outcomes, 8(1), 87-95. [More Information]
• Dinh, M., Green, T., Bein, K., Lo, S., Jones, A., Johnson, T. (2015). Emergency department clinical redesign, team-based care and improvements in hospital performance: A time series analysis. EMA - Emergency Medicine Australasia, 27(4), 317-322. [More Information]
• Wang, A., Bellomo, R., Cass, A., Finfer, S., Gattas, D., Myburgh, J., Chadban, S., Hirakawa, Y., Ninomiya, T., Li, Q., Lo, S., Jardine, M., Gallagher, M., et al (2015). Health-related quality of life in survivors of acute kidney injury: The Prolonged Outcomes Study of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy study outcomes. Nephrology, 20(7), 492-498. [More Information]
• Li, S., Wu, Y., Du, X., Li, X., Patel, A., Peterson, E., Turnbull, F., Lo, S., Billot, L., Laba, T., et al (2015). Rational and design of a stepped-wedge cluster randomized trial evaluating quality improvement initiative for reducing cardiovascular events among patients with acute coronary syndromes in resource-constrained hospitals in China. American Heart Journal, 169(3), 349-355. [More Information]
• Ivers, R., Hunter, K., Clapham, K., Coombes, J., Fraser, S., Lo, S., Gabbe, B., Hendrie, D., Read, D., Kimble, R., Jones, L., Holland, A., et al (2015). Understanding burn injuries in Aboriginal and Torres Strait Islander children: protocol for a prospective cohort study. BMJ Open, 5(10), 1-7. [More Information]

2014

• Dinh, M., Bein, K., Gabbe, B., Byrne, C., Petchell, J., Lo, S., Ivers, R. (2014). A trauma quality improvement programme associated with improved patient outcomes: 21 years of experience at an Australian Major Trauma Centre. Injury, 45(5), 830-834. [More Information]
• Laba, T., Hayes, A., Lo, S., Peiris, D., Usherwood, T., Hillis, G., Rafter, N., Reid, C., Tonkin, A., Webster, R., Neal, B., Patel, A., Rodgers, A., Jan, S., et al (2014). An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial. Medical Journal of Australia, 201(11), 671-673. [More Information]
• Wang, A., Bellomo, R., Ninomiya, T., Lo, S., Cass, A., Jardine, M., Gallagher, M. (2014). Angiotensin converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology, 19(10), 617-622. [More Information]
• Bellomo, R., Cass, A., Cole, L., Finfer, S., Gallagher, M., Lee, J., Lo, S., McArthur, C., McGuinness, S., Myburgh, J., Norton, R., et al (2014). Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care, 18(2), 1-11. [More Information]
• Bellomo, R., Cass, A., Cole, L., Finfer, S., Gallagher, M., Lee, J., Lo, S., McArthur, C., McGuinness, S., Norton, R., Myburgh, J., et al (2014). Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification, 37(4), 325-334. [More Information]
• Keay, L., Palagyi, A., McCluskey, P., Lamoureux, E., Pesudovs, K., Lo, S., Ivers, R., Boufous, S., Morlet, N., Ng, J., et al (2014). Falls in Older people with Cataract, a longitudinal evaluation of impact and risk: the FOCUS study protocol. Injury Prevention, 20(4), 1-6. [More Information]
• Du, X., Gao, R., Turnbull, F., Wu, Y., Rong, Y., Lo, S., Billot, L., Hao, Z., Ranasinghe, I., Iedema, R., Patel, A., et al (2014). Hospital quality improvement initiative for patients with acute coronary syndromes in China: a cluster randomized, controlled trial. Circulation: Cardiovascular Quality and Outcomes, 7(2), 217-226. [More Information]
• Gallagher, M., Cass, A., Bellomo, R., Finfer, S., Gattas, D., Lee, J., Lo, S., McGuinness, S., Myburgh, J., Parke, R., et al (2014). Long-term survival and dialysis dependency following acute kidney injury in intensive care: Extended follow-up of a randomized controlled trial. PLoS Medicine, 11(2), 1-13. [More Information]
• Ma, J., Heritier, S., Lo, S. (2014). On the maximum penalized likelihood approach for proportional hazard models with right censored survival data. Computational Statistics and Data Analysis, 74, 142-156. [More Information]
• Sakashita, C., Jan, S., Senserrick, T., Lo, S., Ivers, R. (2014). Perceived value of a motorcycle training program: the influence of crash history and experience of the training. Traffic Injury Prevention, 15(4), 407-413. [More Information]
• Alsaadi, S., McAuley, J., Hush, J., Lo, S., Lin, C., Williams, C., Maher, C. (2014). Poor sleep quality is strongly associated with subsequent pain intensity in patients with acute low back pain. Arthritis & Rheumatology, 66(5), 1388-1394. [More Information]
• Hudson, H., Lo, S., Simes, R., Tonkin, A., Heritier, S. (2014). Semiparametric methods for multistate survival models in randomised trials. Statistics in Medicine, 33, 1621-1645. [More Information]
• Alsaadi, S., McAuley, J., Hush, J., Lo, S., Bartlett, D., Grunstein, R., Maher, C. (2014). The Bidirectional Relationship Between Pain Intensity and Sleep Disturbance/Quality in Patients with Low Back Pain. Clinical Journal of Pain, 30(9), 755-765. [More Information]
• Sakashita, C., Senserrick, T., Lo, S., Boufous, S., de Rome, L., Ivers, R. (2014). The Motorcycle Rider Behavior Questionnaire: Psychometric properties and application amongst novice riders in Australia. Transportation Research Part F, 22, 126-139. [More Information]
• Bellomo, R., Cass, A., Cole, L., Finfer, S., Gallagher, M., Kim, I., Lee, J., Lo, S., McArthur, C., McGuinness, S., Norton, R., Myburgh, J., et al (2014). The relationship between hypophosphataemia and outcomes during low-intensity and high-intensity continuous renal replacement therapy. Critical Care and Resuscitation, 16(1), 34-41. [More Information]
• Jun, M., Bellomo, R., Cass, A., Gallagher, M., Lo, S., Lee, J. (2014). Timing of Renal Replacement Therapy and Patient Outcomes in the Randomized Evaluation of Normal Versus Augmented Level of Replacement Therapy Study. Critical Care Medicine, 42(8), 1756-1765. [More Information]

2013

• Keay, L., Coxon, K., Brown, J., Clarke, E., Bundy, A., Ivers, R., Lo, S., Boufous, S. (2013). A randomized trial to evaluate the effectiveness of an individual, education-based safe transport program for drivers aged 75 years and older. BMC Public Health, 13, 1-8. [More Information]
• Schneider, A., Bellomo, R., Bagshaw, S., Glassford, N., Lo, S., Jun, M., Cass, A., Gallagher, M. (2013). Choice of renal replacement therapy modality and dialysis dependence after acute kidney injury: a systematic review and meta-analysis. Intensive Care Medicine, 39(6), 987-997. [More Information]
• Bellomo, R., Lipcsey, M., Calzavacca, P., Haase, M., Haase-Fielitz, A., Licari, E., Tee, A., Cole, L., Cass, A., Finfer, S., Gallagher, M., Myburgh, J., et al (2013). Early acid-base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine, 39(3), 429-436. [More Information]
• Gattas, D., Dan, A., Myburgh, J., Billot, L., Lo, S., Finfer, S. (2013). Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Medicine, 39(4), 558-568. [More Information]
• Martiniuk, A., Senserrick, T., Lo, S., Williamson, A., Du, W., Grunstein, R., Woodward, M., Glozier, N., Stevenson, M., Norton, R., Ivers, R. (2013). Sleep-Deprived Young Drivers and the Risk for Crash: The DRIVE Prospective Cohort Study. JAMA Pediatrics, 167(7), 647-655. [More Information]
• Pascoe, E., Lo, S., Scaria, A., Badve, S., Beller, E., Cass, A., Hawley, C., Johnson, D. (2013). The HONEYPOT randomized controlled trial statistical analysis plan. Peritoneal Dialysis International, 33(4), 426-435. [More Information]

2012

• Bellomo, R., Cass, A., Cole, L., Finfer, S., Gallagher, M., Lee, J., Lo, S., McArthur, C., McGuiness, S., Norton, R., et al (2012). An observational study fluid balance and patient outcomes in the randomized evaluation of normal vs. augmented level of replacement therapy trial. Critical Care Medicine, 40(6), 1753-1760. [More Information]
• Asha, S., Curtis, K., Grant, N., Taylor, C., Lo, S., Smart, R., Compagnoni, K. (2012). Comparison of radiation exposure of trauma patients from diagnostic radiology procedures before and after the introduction of a panscan protocol. EMA - Emergency Medicine Australasia, 24(1), 43-51. [More Information]
• Gattas, D., Dan, A., Myburgh, J., Billot, L., Lo, S., Finfer, S. (2012). Fluid resuscitation with 6% hydroxyethyl starch (130/0.4) in acutely ill patients: an updated systematic review and meta-analysis. Anesthesia and Analgesia, 114(1), 159-169. [More Information]
• Lo, S., Ronchetti, E. (2012). Robust small sample accurate inference in moment condition models. Computational Statistics and Data Analysis, 56(11), 3182-3197. [More Information]
• Wong, G., Zoungas, S., Lo, S., Chalmers, J., Cass, A., Neal, B., Woodward, M., Perkovic, V., Glasziou, P., Williams, B., Howard, K., Chapman, J., Craig, J. (2012). The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation, 27(8), 3337-3344. [More Information]

2011

• Heritier, S., Lo, S., Morgan, C. (2011). An adaptive confirmatory trial with interim treatment selection: Practical experiences and unbalanced randomization. Statistics in Medicine, 30(13), 1541-1554. [More Information]

2009

• Bellomo, R., Cass, A., Norton, R., Gallagher, M., Lo, S., Su, S., Cole, C., Finfer, S., McArthur, C., McGuinness, S., Myburgh, J., et al (2009). Intensity of continuous renal-replacement therapy in critically ill patients. New England Journal of Medicine, 361(17), 1627-1638. [More Information]
• Lo, S., Heritier, S., Hudson, M. (2009). Saddlepoint approximation for semi-Markov processes with application to a cardiovascular randomised study. Computational Statistics and Data Analysis, 53(3), 683-698. [More Information]